Docon Technologies Sells 9.9% Stake in Thyrocare for Rs 986 Crore

Docon Technologies, a key promoter of Thyrocare Technologies Ltd, has sold a significant 9.9% stake in the diagnostics company for Rs 986 crore. The transaction, executed through multiple bulk and block deals, saw the offloading of 1,57,69,696 equity shares across the NSE and BSE on Thursday.

Details of the Stake Sale

The shares were sold within a price range of Rs 624 to Rs 631.71 each, culminating in a total transaction value of Rs 985.86 crore. The sale involved more than 1.31 crore shares through block deals and 10 lakh shares via bulk deals on the NSE. Additionally, 16.01 lakh shares were traded in a bulk deal on the BSE.

Following this divestiture, Docon's holding in Thyrocare has decreased from 60.92% to 51.02%. This move marks a continued reduction in Docon's stake, following a previous sale of a 10% stake for Rs 667 crore in October of the previous year.

Investor Interest and Market Reaction

The stake sale attracted a diverse group of buyers, including institutional investors, insurance companies, and global investors. Notable participants included HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Insurance firms such as Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance were also involved, along with international players like Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority.

Market response to the transaction was positive, with Thyrocare Technologies' shares rising nearly 3% to Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE by Friday.

Context and Implications

This sale is part of a broader trend of strategic stake adjustments by Docon Technologies in Thyrocare. The involvement of numerous high-profile investors underscores the continued interest in India's diagnostics sector, driven by both domestic and international players. As the healthcare industry evolves, such transactions highlight the dynamic nature of investment patterns and the strategic rebalancing by major stakeholders.

While details of other buyers in the bulk deals remain undisclosed, the participation of a broad spectrum of investors suggests confidence in Thyrocare's market position and future prospects. The diagnostics industry in India continues to attract attention, with stakeholders keen to capitalize on growth opportunities in the sector.